DK176078B1 - HIV-3 retrovirus og anvendelse heraf - Google Patents
HIV-3 retrovirus og anvendelse heraf Download PDFInfo
- Publication number
- DK176078B1 DK176078B1 DK199000331A DK33190A DK176078B1 DK 176078 B1 DK176078 B1 DK 176078B1 DK 199000331 A DK199000331 A DK 199000331A DK 33190 A DK33190 A DK 33190A DK 176078 B1 DK176078 B1 DK 176078B1
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- protein
- virus
- retrovirus
- proteins
- Prior art date
Links
- 206010020164 HIV infection CDC Group III Diseases 0.000 title claims abstract description 194
- 241001430294 unidentified retrovirus Species 0.000 title claims abstract description 48
- 241000700605 Viruses Species 0.000 claims abstract description 113
- 102000036639 antigens Human genes 0.000 claims abstract description 97
- 108091007433 antigens Proteins 0.000 claims abstract description 97
- 239000000427 antigen Substances 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 25
- 101710090322 Truncated surface protein Proteins 0.000 claims abstract description 25
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 24
- 239000002773 nucleotide Substances 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 208000030507 AIDS Diseases 0.000 claims abstract description 7
- 101710121417 Envelope glycoprotein Proteins 0.000 claims abstract description 7
- 238000003745 diagnosis Methods 0.000 claims abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 326
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 198
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 136
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- 102000004169 proteins and genes Human genes 0.000 claims description 120
- 238000009396 hybridization Methods 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 58
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 40
- 102100034349 Integrase Human genes 0.000 claims description 40
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 claims description 38
- 238000003776 cleavage reaction Methods 0.000 claims description 36
- 230000007017 scission Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 239000000523 sample Substances 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 30
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 239000006166 lysate Substances 0.000 claims description 27
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 20
- 101710149279 Small delta antigen Proteins 0.000 claims description 20
- 101710205625 Capsid protein p24 Proteins 0.000 claims description 19
- 101710142246 External core antigen Proteins 0.000 claims description 19
- 101710152529 Fibrohexamerin Proteins 0.000 claims description 19
- 101710147507 Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 19
- 101710177166 Phosphoprotein Proteins 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 101710132601 Capsid protein Proteins 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 15
- 230000001900 immune effect Effects 0.000 claims description 15
- 238000001262 western blot Methods 0.000 claims description 14
- 108090000288 Glycoproteins Proteins 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 13
- 101710091045 Envelope protein Proteins 0.000 claims description 12
- 101710188315 Protein X Proteins 0.000 claims description 12
- 108700004025 env Genes Proteins 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 101150030339 env gene Proteins 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 239000013060 biological fluid Substances 0.000 claims description 10
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 101710192414 V-type proton ATPase subunit e 1 Proteins 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 102100031780 Endonuclease Human genes 0.000 claims description 8
- 108010042407 Endonucleases Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102100036948 DNA polymerase epsilon subunit 4 Human genes 0.000 claims description 6
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims description 6
- 101800002729 p12 Proteins 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims description 3
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000000877 morphologic effect Effects 0.000 claims description 3
- 108010013377 Retroviridae Proteins Proteins 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- -1 p16 Proteins 0.000 claims description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 2
- 230000010415 tropism Effects 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 claims 2
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229940074386 skatole Drugs 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 100
- 239000002299 complementary DNA Substances 0.000 description 40
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 28
- 230000003612 virological effect Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 108010067390 Viral Proteins Proteins 0.000 description 24
- 239000012228 culture supernatant Substances 0.000 description 21
- 230000000875 corresponding effect Effects 0.000 description 20
- 239000000499 gel Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 18
- 101710177291 Gag polyprotein Proteins 0.000 description 16
- 108020000999 Viral RNA Proteins 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 108010089520 pol Gene Products Proteins 0.000 description 16
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000036436 anti-hiv Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 108700010908 HIV-1 proteins Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000003599 detergent Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 108700004029 pol Genes Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 238000010166 immunofluorescence Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 101150088264 pol gene Proteins 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 8
- 102000007999 Nuclear Proteins Human genes 0.000 description 7
- 108010089610 Nuclear Proteins Proteins 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 108010015780 Viral Core Proteins Proteins 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000037029 cross reaction Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000000376 autoradiography Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229960000633 dextran sulfate Drugs 0.000 description 5
- 108700004026 gag Genes Proteins 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 208000008771 Lymphadenopathy Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 101150098622 gag gene Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- RPGUXSFNXRNACR-UHFFFAOYSA-N 2-hydroxyethyl 2-piperazin-1-ylethanesulfonate Chemical compound OCCOS(=O)(=O)CCN1CCNCC1 RPGUXSFNXRNACR-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101150094765 70 gene Proteins 0.000 description 1
- 241000539689 Alber virus Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000539677 Berant virus Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000250392 Cardamine diphylla Species 0.000 description 1
- 235000001250 Cardamine diphylla Nutrition 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 101100224481 Dictyostelium discoideum pole gene Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101100272679 Enterobacteria phage T4 10 gene Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010001584 Human immunodeficiency virus 2 reverse transcriptase Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101100224484 Mus musculus Pole gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101150073374 Pole gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800001595 Protease/Reverse transcriptase Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001468181 Streptococcus sp. 'group C' Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP88109200 | 1988-06-09 | ||
| EP88109200A EP0345375B1 (fr) | 1988-06-09 | 1988-06-09 | Rétrovirus HIV-3 et son utilisation |
| EP8900643 | 1989-06-08 | ||
| PCT/EP1989/000643 WO1989012094A1 (fr) | 1988-06-09 | 1989-06-08 | Retrovirus hiv-3 et son utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK33190D0 DK33190D0 (da) | 1990-02-08 |
| DK33190A DK33190A (da) | 1990-03-28 |
| DK176078B1 true DK176078B1 (da) | 2006-04-10 |
Family
ID=8199044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK199000331A DK176078B1 (da) | 1988-06-09 | 1990-02-08 | HIV-3 retrovirus og anvendelse heraf |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US5304466A (fr) |
| EP (3) | EP1369427A3 (fr) |
| JP (1) | JP2882654B2 (fr) |
| AT (1) | ATE120234T1 (fr) |
| AU (1) | AU625970B2 (fr) |
| CY (1) | CY2051B1 (fr) |
| DE (1) | DE3853422T2 (fr) |
| DK (1) | DK176078B1 (fr) |
| ES (1) | ES2072853T3 (fr) |
| WO (1) | WO1989012094A1 (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364933A (en) | 1986-03-03 | 1994-11-15 | Institut Pasteur | Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2) |
| EP1369427A3 (fr) * | 1988-06-09 | 2004-05-12 | Innogenetics N.V. | Souches du retrovirus HIV-3 et leur utilisation |
| EP0494317B2 (fr) * | 1990-06-15 | 2000-12-27 | Innogenetics N.V. | Le rétrovirus SIV cpz-ant et ses applications |
| US6667387B1 (en) | 1996-09-30 | 2003-12-23 | N.V. Innogenetics S.A. | HCV core peptides |
| ATE179716T1 (de) | 1992-03-06 | 1999-05-15 | Innogenetics Nv | Verfahren zur bestimmung von peptiden, die immunologisch wichtigen epitopen von hcv zugehörig sind |
| US6709828B1 (en) | 1992-03-06 | 2004-03-23 | N.V. Innogenetics S.A. | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them |
| DE59309207D1 (de) | 1992-10-06 | 1999-01-21 | Dade Behring Marburg Gmbh | Retrovirus aus der HIV-Gruppe und dessen Verwendung |
| DE4405810A1 (de) * | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| GB9410044D0 (en) * | 1994-05-19 | 1994-07-06 | Int Murex Tech Corp | Assay |
| CN1651457B (zh) | 1994-10-20 | 2010-07-28 | 巴斯德研究所 | Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列 |
| US5599662A (en) * | 1995-02-17 | 1997-02-04 | Hoffmann-La Roche Inc. | Oliconucleotide primers and probes for the detection of HIV-1 |
| EP0832113B1 (fr) * | 1995-06-07 | 2004-05-19 | Abbott Laboratories | Peptides destines a la detection du vih-1 |
| US5612473A (en) * | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
| WO1998040744A1 (fr) † | 1997-03-10 | 1998-09-17 | Roche Diagnostics Gmbh | Procede de detection simultanee d'antigenes de vih et d'anticorps de vih |
| US5922533A (en) * | 1997-08-15 | 1999-07-13 | Abbott Laboratories | Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups |
| US6846905B2 (en) | 1997-08-15 | 2005-01-25 | Abbott Laboratories | Antigen constructs useful in the detection and differentiation of antibodies to HIV |
| US7244570B2 (en) | 1998-08-04 | 2007-07-17 | Luminex Molecular Diagnostics, Inc. | Methods and compositions for modulating “marginally indiscriminant” hybridizations |
| US6235479B1 (en) | 1999-04-13 | 2001-05-22 | Bio Merieux, Inc. | Methods and devices for performing analysis of a nucleic acid sample |
| DE60041489D1 (de) * | 1999-07-09 | 2009-03-19 | Gen Probe Inc | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren |
| CA2391560A1 (fr) | 1999-11-16 | 2001-05-25 | Geneart Gmbh Gessellschaft Fur Angewandte Biotechnologie | Genome de l'inter-sous-type vih-1 (c/b') et ses applications |
| US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20040002063A1 (en) * | 2002-05-16 | 2004-01-01 | Medmira Inc. | Rapid vaccinia antibody detection device, method and test kit |
| US7556814B2 (en) * | 2003-10-23 | 2009-07-07 | Karp Nelson M | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane |
| ES2528901T3 (es) | 2007-10-22 | 2015-02-13 | Amorphical Ltd. | Carbonato de calcio amorfo estable que comprende aminoácidos fosforilados, péptidos fosforilados sintéticos y proteínas gastrolíticas |
| EP2550362B1 (fr) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Glycoprotéines du cmv et vecteurs recombinés |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (fr) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Trimères de glycoprotéines d'enveloppe du vih -1 soluble |
| EP3069730A3 (fr) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| EP3072901A1 (fr) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| CN107921060A (zh) | 2015-06-04 | 2018-04-17 | 艾玛菲克有限公司 | 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物 |
| US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217861A (en) * | 1983-09-15 | 1993-06-08 | Institut Pasteur | Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor |
| DE122005000039I1 (de) * | 1984-10-18 | 2006-02-23 | Pasteur Institut | DNS-Fragmente des GAG-Gens von LAV |
| US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
| US5066782A (en) * | 1986-01-22 | 1991-11-19 | Institut Pasteur | Retrovirus capable of causing AIDS, means and method for detecting it in vitro |
| ATE47725T1 (de) * | 1986-01-22 | 1989-11-15 | Pasteur Institut | Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile. |
| US5030714A (en) * | 1986-06-23 | 1991-07-09 | Institut Pasteur | Variant of LAV viruses |
| US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
| SE8701765L (sv) * | 1987-04-28 | 1988-10-29 | Statens Bakteriologiska Lab | Analysmetod och medel foer denna |
| EP1369427A3 (fr) * | 1988-06-09 | 2004-05-12 | Innogenetics N.V. | Souches du retrovirus HIV-3 et leur utilisation |
-
1988
- 1988-06-09 EP EP03008364A patent/EP1369427A3/fr not_active Withdrawn
- 1988-06-09 EP EP88109200A patent/EP0345375B1/fr not_active Expired - Lifetime
- 1988-06-09 EP EP94110658A patent/EP0657532B1/fr not_active Revoked
- 1988-06-09 DE DE3853422T patent/DE3853422T2/de not_active Expired - Lifetime
- 1988-06-09 ES ES88109200T patent/ES2072853T3/es not_active Expired - Lifetime
- 1988-06-09 AT AT88109200T patent/ATE120234T1/de not_active IP Right Cessation
-
1989
- 1989-06-08 WO PCT/EP1989/000643 patent/WO1989012094A1/fr unknown
- 1989-06-08 US US07/460,913 patent/US5304466A/en not_active Expired - Lifetime
- 1989-06-08 JP JP1506144A patent/JP2882654B2/ja not_active Expired - Lifetime
- 1989-06-08 AU AU37628/89A patent/AU625970B2/en not_active Expired
-
1990
- 1990-02-08 DK DK199000331A patent/DK176078B1/da not_active IP Right Cessation
-
1994
- 1994-04-15 US US08/228,519 patent/US5567603A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/474,360 patent/US5858647A/en not_active Expired - Lifetime
- 1995-06-07 US US08/486,836 patent/US5795743A/en not_active Expired - Lifetime
-
1997
- 1997-07-25 US US08/900,902 patent/US6013484A/en not_active Expired - Lifetime
-
1998
- 1998-04-30 CY CY9802051A patent/CY2051B1/xx unknown
-
1999
- 1999-08-23 US US09/379,270 patent/US6265200B1/en not_active Expired - Fee Related
-
2001
- 2001-05-09 US US09/851,664 patent/US20030039954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CY2051B1 (en) | 1998-04-30 |
| JP2882654B2 (ja) | 1999-04-12 |
| EP0345375B1 (fr) | 1995-03-22 |
| US5858647A (en) | 1999-01-12 |
| US5795743A (en) | 1998-08-18 |
| DE3853422D1 (de) | 1995-04-27 |
| US5567603A (en) | 1996-10-22 |
| EP0345375A1 (fr) | 1989-12-13 |
| DK33190D0 (da) | 1990-02-08 |
| US6265200B1 (en) | 2001-07-24 |
| EP1369427A2 (fr) | 2003-12-10 |
| EP1369427A3 (fr) | 2004-05-12 |
| EP0657532B1 (fr) | 2003-12-17 |
| US20030039954A1 (en) | 2003-02-27 |
| AU3762889A (en) | 1990-01-05 |
| DK33190A (da) | 1990-03-28 |
| US6013484A (en) | 2000-01-11 |
| US5304466A (en) | 1994-04-19 |
| DE3853422T2 (de) | 1995-10-26 |
| JPH02504583A (ja) | 1990-12-27 |
| ATE120234T1 (de) | 1995-04-15 |
| ES2072853T3 (es) | 1995-08-01 |
| AU625970B2 (en) | 1992-07-23 |
| EP0657532A1 (fr) | 1995-06-14 |
| WO1989012094A1 (fr) | 1989-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK176078B1 (da) | HIV-3 retrovirus og anvendelse heraf | |
| De Leys et al. | Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin | |
| US5055391A (en) | Method and kit or detecting antibodies to antigens of human immunodeficiency virus type 2 (hiv-2) | |
| Earl et al. | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses | |
| Norrby et al. | Discrimination between antibodies to HIV and to related retroviruses using site-directed serology | |
| US6869608B2 (en) | Peptides derived from a retrovirus of the HIV group and their use | |
| Schnittman et al. | Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. | |
| Böttiger et al. | Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site | |
| US5597896A (en) | Retrovirus human immunodeficiency virus type 2(HIV2), capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes | |
| US7115363B1 (en) | Retrovirus capable of causing AIDS, means and methods for detecting it in vitro | |
| US5268265A (en) | Immunological complex comprising an antigen of Simian Immunodeficiency Virus (SIV) and an antibody against human immunodeficiency virus type 2 (HIV 2), and method and kit for detecting antibodies to HIV-2 reactive with antigens of SIV | |
| WO1987002892A1 (fr) | Virus t-lymphotrophique | |
| KR910002428B1 (ko) | Aids를 유발시킬수 있는 신규 레트로비루스의 제조방법 | |
| Baillou et al. | Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV-2/simian immunodeficiency virus | |
| Ljunggren et al. | Antibody-dependent cellular cytotoxicity detects type-and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates | |
| Peeters et al. | Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions | |
| US5624795A (en) | Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant | |
| Modrow et al. | Carrier bound synthetic oligopeptides in ELISA test systems for distinction between HIV-1 and HIV-2 infection | |
| ES2210244T3 (es) | Cepas de retrovirus hiv-3 y su uso. | |
| GOUDSMIT et al. | Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein | |
| Gnann Jr et al. | Using synthetic peptide reagents to distinguish infections caused by different HIV strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |